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Abstract
Background: The risk factors, microbial etiology, differentiation, and clinical features of purulent and non-purulent
cellulitis are not well defined in Taiwan.
Methods: We conducted a retrospective cohort study of hospitalized adults with cellulitis in Taiwan in 2013. The
demographic characteristics, underlying diseases, clinical manifestations, laboratory and microbiological findings,
treatments, and outcomes were compared for patients with purulent and non-purulent cellulitis.
Results: Of the 465 patients, 369 had non-purulent cellulitis and 96 had purulent cellulitis. The non-purulent group
was significantly older (p = 0.001) and was more likely to have lower limb involvement (p < 0.001), tinea pedis
(p = 0.003), stasis dermatitis (p = 0.025), a higher Charlson comorbidity score (p = 0.03), and recurrence at 6 months
post-infection (p = 0.001) than the purulent group. The purulent group was more likely to have a wound (p < 0.001)
and a longer hospital stay (p = 0.001) and duration of antimicrobial therapy (p = 0.003) than the non-purulent group.
The etiological agent was identified in 35.5 % of the non-purulent cases, with β-hemolytic streptococci the most
frequent cause (70.2 %). The etiological agent was identified in 83.3 % of the purulent cases, with Staphylococcus aureus
the predominant pathogen (60 %): 50 % of these were methicillin-resistant S. aureus (MRSA). In multivariable analysis,
purulent group (odds ratio (OR), 5.188; 95 % confidence interval (CI), 1.995–13.493; p = 0.001) was a positive predictor of
MRSA. The prescribed antimicrobial agents were significantly different between the purulent and non-purulent groups,
with penicillin the most frequently used antimicrobial agent in the non-purulent group (35.2 %), and oxacillin the most
frequent in the purulent group (39.6 %). The appropriate antimicrobial agent was more frequently prescribed in the
non-purulent group than in the purulent group (83.2 % vs. 53.8 %, p < 0.001).
Conclusions: The epidemiology, clinical features, and microbiology of purulent and non-purulent cellulitis were
significantly different in hospitalized Taiwanese adults. Purulence was a positive predictor of MRSA as the causal agent
of cellulitis. These findings provide added support for the adoption of the IDSA guidelines for empirical antimicrobial
therapy of cellulitis in Taiwan.
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Background
Cellulitis is a diffuse, spreading infection that involves
the dermis and subcutaneous tissues of the skin. Predis-
posing factors include prior trauma (e.g. abrasion, lacer-
ation, puncture wounds), tinea pedis, stasis dermatitis,
compromised lymphatic drainage, and venous insuffi-
ciency. It is often difficult to make a microbiological
diagnosis because of the low recovery rate from needle
aspirates, skin biopsies, and blood cultures [1, 2], and
because of the identification of widely different causative
organisms depending on the diagnostic tests used [3–5].
A confounding factor is the emergence of community-
associated methicillin-resistant Staphylococcus aureus
(CA-MRSA). Until the mid-1990s, MRSA infections were
limited to hospitals. However, within the last decade,
MRSA outbreaks have been seen in healthy individuals
without connection to healthcare institutions [6]. CA-
MRSA differs from healthcare-associated MRSA (HA-
MRSA) in several ways, including a more limited antibiotic
resistance profile, exotoxin gene profile (Panton Valentine
leukocidin), type of staphylococcal cassette chromosome
mec (SCCmec) gene, and clinical spectrum [7–9]. Infections
of the skin and soft tissues account for 72–86 % of CA-
MRSA cases [7, 8, 10]. The clinical manifestations range
from mild skin and soft tissue infections, cutaneous ab-
scesses, and purulent cellulitis [11, 12], to severe, life-
threatening infections, including pyomyositis and myositis
[13]. CA-MRSA is now the most important pathogen in
purulent skin and soft tissue infections in the United States
and Asia [11, 14].
The 2011 Infectious Diseases Society of America (IDSA)
guidelines for the management of MRSA emphasize the
need to distinguish purulent from non-purulent infections
to clarify the relative contributions of β-hemolytic strepto-
cocci and S. aureus and their implications for antimicro-
bial therapy [15]. The epidemiology, microbiology, clinical
manifestations, and contribution of CA-MRSA to non-
purulent and purulent cellulitis are not well defined in
Taiwan. In Taiwan, initial therapy for cellulitis is often em-
pirical, using broad-spectrum coverage without adequate
distinction between the microbiological etiology of non-
purulent and purulent cellulitis.
This 1-year retrospective cohort study, conducted at
Kaohsiung Veterans General Hospital in Southern Taiwan,
was initiated to better understand the epidemiology, clinical
features, and microbiology of non-purulent and purulent
cellulitis in hospitalized Taiwanese adults. The findings are
to be used as a basis for the development of guidelines for
the diagnosis and management of cellulitis in Taiwan.
Methods
Study design
We conducted a 1-year retrospective cohort study, from
January to December 2013, of the medical records of all
adult patients admitted with the diagnosis of cellulitis to
the Kaohsiung Veterans’ General Hospital (KVGH).
KVGH is a 1200-bed general and tertiary care hospital
located in Southern Taiwan. In our initial investigation,
chart review of cases with International Classification of
Disease, Ninth Revision, Clinical Modification (ICD-9-CM)
codes of 729.4 (fasciitis), 728.86 (necrotizing fasciitis), and
608.83 (Fournier’s gangrene) were also carried out. Al-
though some cases were initially diagnosed as cellulitis
because of spreading erythema and swelling, these were
finally diagnosed as deeper skin and soft tissue infections,
and were not included in our study. The inclusion criteria
were based on ICD-9-CM codes 528.3, 608.4, 681.00–
681.9, and 682.0–682.9. Patients aged ≤20 years or those
found not to have cellulitis on chart review were excluded
from the study. The cases that met the inclusion criteria
were further divided into non-purulent and purulent
groups according to the definitions provided below.
The two groups were then compared for demographic
characteristics, underlying diseases, clinical manifesta-
tions, laboratory findings, diagnostic methods, patho-
gen, and outcomes. The study was approved by the
ethical committee of Kaohsiung Veterans General Hos-
pital (VGHKS14-CT12-01).
Data collection
Hospital records were retrieved and relevant epidemio-
logical, clinical, and microbiological data were compiled.
Outcomes included length of hospital stay, antimicrobial
therapy, 30-day all-cause and cellulitis-related mortality,
and recurrent episodes of cellulitis at the initial site at
6 months post-infection.
Definitions
Wound is defined as a pre-existing skin lesion at the
time of skin infection onset, such as a chronic ulcer, or a
trauma-related skin lesion, such as lacerations, abra-
sions, or punctures. Surgical site infection is not in-
cluded in the present study.
Purulent cellulitis was initially defined as skin lesions
associated with purulent drainage or exudate in the ab-
sence of a drainable abscess [15]. A cutaneous abscess
was defined as a collection of pus within the dermis and
deeper skin tissues [16]. Because of the difficulties associ-
ated with differentiating purulent cellulitis from cutaneous
abscess in a retrospective chart review, we combined these
two presentations into the purulent group. Non-purulent
cellulitis was defined as cellulitis without purulent drain-
age or exudate or associated abscess [15].
CA-MRSA was defined as MRSA isolated from a patient
who had none of the following established risk factors for
HA-MRSA. These included isolation of MRSA > 48 h
after hospital admission, history of prior hospitalization,
surgery, dialysis, or residence in a long-term care facility
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within the previous year, the presence of an indwelling
urinary catheter or a percutaneous device at the time of
culture, or previous isolation of MRSA [17, 18]. Modified
case definition, which excludes the previous isolation of
MRSA as a criterion for HA-MR, was also analyzed in the
present study [19].
An appropriate antimicrobial agent was defined as an
antimicrobial agent to which the identified pathogen was
susceptible.
Recurrence of cellulitis was defined as an attack of cel-
lulitis in the same anatomical site within 6 months of
cure of the previous episode of cellulitis.
Microbiological studies
Bacteria were identified and antimicrobial susceptibility
profiles were determined using a Vitek two automated
system (bioMérieux, Canada) at the KVGH Clinical
Microbiology Laboratory. All S. aureus isolates suscep-
tible to oxacillin underwent confirmatory disk diffusion
testing for cefoxitin susceptibility. MRSA isolates were
tested for susceptibility to erythromycin, clindamycin,
levofloxacin, rifampin, trimethoprim-sulfamethoxazole,
and vancomycin. The D-test was performed to detect in-
ducible clindamycin resistance for isolates that were re-
sistant to erythromycin, but susceptible to clindamycin.
All tests were performed and interpreted in accordance
with Clinical and Laboratory Standards Institute guide-
lines (M100-S19).
Blood and pus cultures, skin biopsy, and serological
antistreptolysin O titer (ASOT) reports were collected
and analyzed. Coagulase-negative staphylococci, diph-
theroids, and Bacillus species were considered to be
blood culture contaminants when isolated from one cul-
ture bottle of a set, or when another set of blood culture
bottles was sterile. A positive wound culture was defined
as isolation of a bacterium from both a superficial and a
deep site. The term β-hemolytic streptococci was used
rather than Streptococcus pyogenes because the isolates
were not differentiated by group. When both acute and
convalescent ASOT results were not available to demon-
strate a ≥2-fold increase in titer, a single positive ASOT
with a titer of ≥200 U/mL, according to the manufac-
turer, was considered to be positive.
Statistical analysis
All statistical analyses were performed using SPSS version
12.0 (SPSS, Chicago, IL, USA). Descriptive statistics were
used to summarize the characteristics of the patients and
the relative contributions of the non-purulent and puru-
lent groups. Categorical variables were compared between
these two groups using the χ2 or Fisher’s exact tests, and
continuous variables were compared using an independent
t-test. All tests were 2-tailed, and p < 0.05 was considered
significant. Multivariable analyses of predictive factors for
MRSA were performed in patients with a final pathogen
diagnosis using the LOGISTIC procedure, and the candi-
date variables were identified as those having a univariate
significance of p ≤ 0.10, those identified in a previous
study, or those believed to be clinically meaningful.
Results
Demographic characteristics and underlying diseases in
patients with cellulitis
We reviewed the medical records of 968 patients initially
identified as having cellulitis. We excluded 503 cases
(52.0 %) for the following reasons: infections other than
cellulitis (382; 75.9 %), age ≤20 years (85; 16.9 %), non-
infectious diseases (33; 6.6 %), and incomplete records
(3; 0.6 %). The study population consisted of the
remaining 465 patients, of which 369 (79.4 %) had non-
purulent and 96 (20.6 %) had purulent cellulitis. Their
demographic characteristics and underlying diseases are
summarized in Table 1. The median age was 62 years
(range, 20–96 years; SD ± 20.2); 61.3 % were men. The
non-purulent group was significantly older (64 vs.
56 years, p = 0.001) and more likely to have tinea pedis
(18.7 % vs. 6.3 %, p = 0.003), stasis dermatitis (7.0 % vs.
1.0 %, p = 0.025), and a higher Charlson comorbidity
score (1.5 vs. 1.1, p = 0.03) than the purulent group. The
purulent group was more likely to have a wound (44.9 %
vs. 22.8 %, p < 0.001) than the non-purulent group.
There were no significant differences between the two
groups in gender composition.
Clinical and laboratory manifestations of patients with
cellulitis
The clinical and laboratory findings for the 465 cases of
cellulitis are summarized in Table 2. There were no sig-
nificant differences between the two groups in frequency
of sepsis at admission or clinical laboratory findings.
Cellulitis was localized to the lower extremities, upper
extremities, and head and neck in 78.7, 8.6, and 7.5 % of
cases, respectively. Although lower extremity cellulitis
was the most common site of infection in both groups,
it was significantly more frequent in the non-purulent
than the purulent group (82.4 % vs. 62.5 %, p < 0.001).
Microbiological and serological studies
Microbiological and/or serological studies were per-
formed in 91.6 % of cases in the non-purulent group
and in 97.9 % of cases in the purulent group (Table 3).
Wound culture, blood culture, ASOT, and skin biopsy
were performed in 33.3, 75.5, 45.2, and 0.2 % of cases,
respectively. One or more bacterial species were isolated
from 110 of the 155 (71.0 %) wound cultures. Of the 110
patients with a positive wound culture, 15 (13.6 %) had
superficial and 95 (86.4 %) had deep wounds. The preva-
lence of positive wound culture was higher in the
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purulent group than in the non-purulent group (88.6 %
vs. 47.8 %, p < 0.001). Thirty-three of the 351 blood cul-
tures (9.4 %) met the criterion for a positive culture.
There was no significant difference in the prevalence of
positive blood cultures between the non-purulent and
purulent groups (8.2 % vs. 15.0 %, p = 0.103). Of the 210
patients with measured ASOT, paired acute and conva-
lescent ASOT was collected in 18 non-purulent cases,
but no purulent cases. A positive ASOT as defined above
was noted in 84 of the 210 patients (40.0 %). The
ASOT-positive rate was higher in the non-purulent than
the purulent group (42.8 % vs. 11.1 %, p = 0.03).
Table 1 Demographic characteristics and underlying diseases among 465 cellulitis cases
All (n = 465) Non-purulent group (n = 369) Purulent group (n = 96) P-value
Age (years), mean (SD) 62 (20.2) 64 (19.4) 56 (21.9) 0.001
Male sex, no. (%) 285 (61.3) 221 (59.9) 64 (66.7) 0.225
Wound (%) 123 (26.5) 84 (22.8) 39 (40.9) <0.001
Charlson comorbidity score, mean (SD) 1.4 (1.6) 1.5 (1.6) 1.1 (1.5) 0.03
Diabetes mellitus (%) 119 (25.9) 101 (27.4) 18 (18.8) 0.085
Autoimmune disease (%) 16 (3.4) 13 (3.5) 3 (3.1) 1.00
Solid malignancy (%) 65 (14) 56 (15.2) 9 (9.4) 0.144
Hematological malignancy (%) 13 (2.8) 12 (3.3) 1 (1.0) 0.484
Liver cirrhosis (%) 29 (6.2) 20 (5.4) 9 (9.4) 0.153
HIV infection (%) 4 (0.9) 3 (0.8) 1 (1.0) 1.00
Organ transplantation (%) 2 (0.4) 2 (0.5) 0 (0.0) 1.00
Chronic obstructive pulmonary disease (%) 13 (2.8) 9 (2.4) 4 (4.2) 0.318
Peripheral artery occlusive disease (%) 18 (3.9) 14 (3.8) 4 (4.2) 0.773
Coronary artery bypass graft (%) 11 (2.4) 9 (2.4) 2 (2.1) 1.00
Fracture (%) 9 (1.9) 9 (2.4) 0 (0.0) 0.215
Flap (%) 9 (1.9) 9 (2.4) 0 (0.0) 0.215
Lymph node dissection (%) 21 (4.5) 19 (5.1) 2 (2.1) 0.273
Tinea pedis (%) 75 (18.1) 69 (18.7) 6 (6.3) 0.003
Stasis dermatitis (%) 27 (5.8) 26 (7.0) 1 (1.0) 0.025
Data are no. (%) of patients, unless otherwise indicated
Table 2 Clinical manifestations, laboratory findings, and outcomes among 465 cellulitis cases
All (n = 465) Non-purulent group (n = 369) Purulent group (n = 96) P-value
Lower extremities involved (%) 364 (78.3) 304 (82.4) 60 (62.5) <0.001
Sepsis at admission (%) 127 (27.3) 103 (27.9) 24 (25.0) 0.568
WBC, mean 109/L (SD) 10.3 (4.9) 10.2 (5.0) 10.5 (4.8) 0.572
Hb (g/dL), mean (SD) 12.9 (2.2) 12.9 (2.2) 13.0 (2.3) 0.658
PLT/mm3 (SD) 200.6 (78.9) 195.0 (77.2) 221.9 (82) 0.003
Lactic acid (mmol/L), mean (SD) 1.8 (1.2) 1.8 (1.2) 1.9 (1.3) 0.917
Cr (mg/dL), mean (SD) 1.3 (1.7) 1.4 (1.9) 1.1 (0.7) 0.175
CK (U/L), mean (SD) 142.1 (343) 144.2 (368) 131.8 (165.9) 0.813
CRP (mg/dL), mean (SD) 6.3 (7.6) 6.3 (7.7) 6.3 (7.4) 0.993
GOT (IU/L), mean (range) 31.0 (23.6) 30.4 (19.8) 33.2 (34.4) 0.5
Albumin (g/dL), mean (SD) 3.1 (0.7) 3.1 (0.7) 3.2 (0.6) 0.71
Recurrence within 6 months (%) 57 (12.3) 54 (14.6) 3 (3.1) 0.001
Death within 30 days (%) 3 (0.6) 3 (0.8) 0 (0) 1.0
Length of stay, days (SD) 9 (6.5) 8 (5.8) 11 (8.1) 0.001
Duration of antimicrobial therapy, days (SD) 14 (9.7) 13 (9) 17 (12) 0.003
Data are number (%) of patients, unless otherwise indicated
CK creatine kinase, Cr creatinine, CRP C-reactive protein, GOT glutamate oxaloacetate transaminase, Hb hemoglobin, PLT platelet count, SD standard deviation
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Microbiological findings
The etiological agent(s) were identified from one or
more sites or by serology in 211 of the 465 patients
(45.4 %) (Table 4). The causative bacteria were identified
in 35.5 % of the non-purulent cases and 83.3 % of the
purulent group. β-hemolytic streptococci were the pre-
dominant bacterial pathogens among patients with non-
purulent cellulitis with positive microbiological findings,
accounting for 70.2 % of cases (92/131). β-hemolytic
streptococci were identified by wound culture (three
cases, 3.3 %), ASOT (76 cases, 82.6 %), blood culture
(seven cases, 7.6 %), or ASOT and blood culture (six
cases, 6.5 %). The next most frequently identified bac-
teria in the non-purulent group were S. aureus (12.2 %),
Gram-negative bacilli (9.9 %), and polymicrobial patho-
gens (4.6 %). S. aureus was the most common pathogen
(60.0 %) amongst the 80 patients in the purulent group
with positive microbiological findings, followed by poly-
microbial pathogens (18.8 %), Gram-negative bacilli
(12.5 %), and β-hemolytic streptococci (5.0 %). MRSA
were more frequently isolated from the purulent than
the non-purulent group (30.0 % vs. 6.1 %, p < 0.001).
CA-MRSA, defined by both epidemiological criteria
[17–19] reported the same number of cases, and were
isolated in 21.3 % of cases in the purulent group and
3.8 % of cases in the non-purulent group (p = 0.681).
Antimicrobial susceptibility of MRSA stratified by
CA-MRSA criteria
The antimicrobial susceptibility profiles of the 32 MRSA
isolates were shown in Table 5. There was no significant
difference in antimicrobial susceptibility between CA-
MRSA and non-CA-MRSA isolates.
Multivariable analyses of predictive factors for MRSA
infection in 211 cases with a final pathogen diagnosis
Following adjustment for age, sex, sepsis, lower limb in-
volvement, history of tinea pedis, diabetes, and wound,
purulence was a positive predictor of MRSA infection
(odds ratio (OR), 5.188; 95 % confidence interval (CI),
1.995–13.493; p = 0.001) (Table 6).
Table 3 Diagnostic testsa and associated results
All (n = 465) Non-purulent group (n = 369) Purulent group (n = 96) P-value
Diagnostic testa performed (%) 432 (92.9) 338 (91.6) 94 (97.9) 0.032
Wound culture (%) 155 (33.3) 67 (18.2) 88 (91.7) <0.001
Positive prevalence (%) 110 (71) 32 (47.8) 78 (88.6) <0.001
Blood culture (%) 351 (75.5) 291 (78.9) 60 (62.5) 0.001
Positive prevalence (%) 33 (9.4) 24 (8.2) 9 (15) 0.103
ASOT (%) 210 (45.2) 192 (52.0) 18 (18.8) <0.001
Positive prevalence (%) 84 (40.0) 82 (42.8) 2 (11.1) 0.031
One set 72 (34.3) 70 (36.5) 2 (11.1)
Paired 12 (5.7) 12 (6.3) 0 (0.0)
Puncture biopsy (%) 1 (0.2) 1 (0.3) 0 (0.0) 1.000
Positive prevalence (%) 0 0 0
Data are number (%) of patients, unless otherwise indicated
ASOT antistreptolysin O titer
aIt means blood culture, wound culture, ASOT, and puncture biopsy
Table 4 Microbiological diagnosis in non-purulent (n = 131) and purulent cellulitis (n = 80) cases
All (n = 211) Non-purulent group (n = 131) Purulent group (n = 80) P-value
β-Hemolytic streptococci (%) 96 (45.5) 92 (70.2) 4 (5.0) <0.001
Staphylococcus aureusa (%) 64 (30.3) 16 (12.2) 48 (60.0) <0.001
MRSAb (%) 32 (15.2) 8 (6.1) 24 (30.0) <0.001
CA-MRSAc (%) 22 (10.4) 5 (3.8) 17 (21.3) 0.681
GNB (%) 23 (10.9) 13 (9.9) 10 (12.5) 0.441
Polymicrobial pathogens (%) 21 (10.0) 6 (4.6) 15 (18.8) 0.001
Data are number (%) of patients, unless otherwise indicated
CA-MRSA community-associated methicillin-resistant Staphylococcus aureus, GNB Gram-negative bacilli
aIncluding methicillin-susceptible S. aureus and methicillin-resistant S. aureus
bIncluding CA-MRSA and non-CA-MRSA
cDefined by epidemiological criteria [17–19], not by genotypic criteria
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Empirical prescription of antimicrobial agents
The empirical prescription of antimicrobial agents is de-
tailed in Table 7. In this study, the five most commonly
prescribed antimicrobial agents were penicillin (29.5 %),
oxacillin (28.6 %), cefazolin (19.4 %), β-lactam/β-lacta-
mase inhibitors (3.7 %), and penicillin plus clindamycin
(3.4 %). The prescription of antimicrobial agents differed
significantly between the purulent and non-purulent
groups. Penicillin was the most frequently prescribed
agent in the non-purulent group (35.2 %), whereas oxa-
cillin was the most frequently prescribed agent in the
purulent group (39.6 %). The appropriate antimicrobial
agent was more frequently prescribed in the non-
purulent group than in the purulent group (83.2 % vs.
53.8 % of cases, p < 0.001). Among the 32 cases of
MRSA identified, 12.5 % (4/32) of cases received the ap-
propriate antibiotic therapy, and the prevalence of ap-
propriate antimicrobial agent use was not significantly
different between the purulent and non-purulent groups
(16.7 % vs. 0 %, p = 0.55).
Outcomes
The length of hospital stay and duration of antimicrobial
therapy were shorter for the non-purulent group com-
pared with the purulent group (8 vs. 11 days, p = 0.001;
13 vs. 17 days, p = 0.003, respectively). More patients
underwent surgery in the purulent group than in the
non-purulent group (49 % vs. 4.1 %, p < 0.001), and re-
currence within 6 months post-infection was higher in
the non-purulent group than in the purulent group
(14.6 % vs. 3.1 %, p = 0.001). Three of the 465 patients
(0.6 %) died within 6 months of discharge. None of the
deaths were attributable to cellulitis.
Discussion
The risk factors and the clinical and microbiological fea-
tures of purulent and non-purulent cellulitis among hospi-
talized Taiwanese adults in the current study were
remarkably similar to those reported in Western countries
[20–24]. In the present study, patients with non-purulent
cellulitis were more likely to have lower limb involvement,
stasis dermatitis, and tinea pedis, along with a higher like-
lihood of recurrence than those with purulent cellulitis.
Patients with purulent cellulitis were more likely to have
wounds than those with non-purulent cellulitis. As in
other studies, β-hemolytic streptococci were the predom-
inant pathogens in the non-purulent group [2, 25], and S.
aureus was the most common pathogen in the purulent
group [11].
Cellulitis is a relatively common infectious disease in both
children and adults. To ensure proper treatment, it needs
to be differentiated from focal infections with surrounding
inflammation, such as septic bursitis, osteomyelitis and sep-
tic arthritis, and non-infectious inflammatory diseases. We
excluded 503 of the original 968 patients (52.0 %) because
of misdiagnoses. The three most common misdiagnosed
Table 5 Antibiotic susceptibilities of 32 MRSA isolates, stratified by CA-MRSA criteria
Antibiotic No. (%) of samples, by susceptibility
Epidemiological classification
CA-MRSA (n = 22) Non CA-MRSA (n = 10) P-value
Chloramphenicol (%) 12 (54.5) 7 (70) 0.467
Clindamycin (%)a 4 (19) 0 (0) 0.287
Erythromycin (%) 4 (18.2) 0 (0) 0.283
Minocycline (%) 20 (95.2) 8 (80) 0.237
Levofloxacin (%) 18 (81.8) 5 (50) 0.096
Rifampin (%) 22 (100) 8 (80) 0.091
TMP-SMX (%) 21 (95.5) 7 (70) 0.079
Vancomycin (%) 22 (100) 10 (100) 1.000
Data are number (%) of patients, unless otherwise indicated
TMP-SMX trimethoprim-sulfamethoxazole
aSusceptibility to clindamycin was determined for 21 CA-MRSA isolates and nine non-CA-MRSA isolates. The D-test was performed to detect inducible clindamycin
resistance for isolates found to be resistant to erythromycin, but susceptible to clindamycin
Table 6 Multivariable analysis of risk factors for MRSA infection
in the 211 adult patients with final pathogen diagnosis
Variables OR 95 % CI p value
Age 0.994 0.974–1.014 0.529
Sex (male) 1.050 0.435–2.534 0.914
Sepsis 0.873 0.353–2.160 0.769
Lower limb involvement 0.777 0.283–2.137 0.625
Tinea pedis 0.490 0.102–2.366 0.375
Diabetes mellitus 0.391 0.105–1.455 0.161
Purulent group 5.188 1.995–13.493 0.001
Wound 1.122 0.420–2.994 0.819
Lee et al. BMC Infectious Diseases  (2015) 15:311 Page 6 of 9
infections were anorectal abscess (n = 84), deep layer in-
volvement (n = 64), and odontogenic infection (n = 37). The
three most common misdiagnosed non-infectious diseases
were phlebitis (n = 42), deep vein thrombosis (n = 7), and
tumor with central necrosis (n = 5).
A large study conducted in emergency departments
across the United States demonstrated that 76 % of cases
of purulent soft tissue infection were caused by S. aur-
eus, 59 % of which were CA-MRSA [11]. The present
study demonstrates similar results. Of the purulent cases
in which the etiological agent was identified, 60 % were
caused by S. aureus, 35.4 % of which were CA-MRSA. A
prospective study of 179 patients with non-purulent cel-
lulitis based on acute and convalescent sera for ASO
and DNase-B antibodies found that 73 % of cases had
serological evidence of β-hemolytic Streptococcal infec-
tion [2]. A recently published prospective study of 77
cases with non-necrotizing cellulitis using serological
study of Streptococcus also demonstrated similar results
[25]. In the present study, however, the serological evi-
dence of streptococcus infection may be underestimated
in the non-purulent group because paired acute and
convalescent ASOT were collected in only 18 cases,
66.7 % (12/18) of which were positive. 90.6 % (174/192)
cases with measured ASOT in the non-purulent group
received only a single ASOT, and the prevalence of posi-
tive ASOT was 40.2 % (70/174).
An increased ASOT between the acute and convales-
cent phases provides a more accurate reflection of a pre-
ceding streptococcal infection than a single titer [26].
However, it is not always feasible to obtain paired sera.
Therefore, the occurrence of a single isolated titer that is
higher than the upper limit of normal value is also evi-
dence of a previous streptococcal infection. In patients
with group A streptococcal infections, ASOT begins to
rise after approximately 1 week, reaching maximal levels
at 3–6 weeks post-infection [27, 28], and begins to de-
cline in uncomplicated infections at 6–8 weeks post-
infection, although in some patients the titer may re-
main elevated for indefinite periods [29]. We reviewed
the charts of the 70 non-purulent cases with a single
positive ASOT in the current study, which showed that
only six of these cases experienced another episode of
cellulitis in the year preceding the current episode.
These findings provide further support for β-hemolytic
streptococci being the causal organism in the majority of
the 70 cases with a single positive ASOT.
The lower rate of ASOT performed in the purulent
group compared with the non-purulent group may have
led to an underestimation of the incidence of Streptococ-
cus infection (purulent vs. non-purulent, 18.8 % vs.
52.0 %, p <0.001). This selection bias is unavoidable in a
retrospective study, but may be limited. First, the lower
rate of ASOT testing in the purulent group may reflect
the fact that these patients did not present with typical
Streptococcus cellulitis, which is characterized by rapidly
spreading areas of inflammation in the lower extremities,
sometimes accompanied by lymphangitis and regional
lymphadenitis in cases with predisposing conditions,
such as tinea pedis, stasis dermatitis, compromised
lymphatic drainage, and venous insufficiency. Second,
the prevalence of positive ASOT, whether as single or
paired results, was significantly lower in the purulent
group than in the non-purulent group (purulent vs. non-
purulent, 11.1 % vs. 42.75 %, p = 0.031).
In the present study, cellulitis cases were treated by a
range of practitioners, including primary care, emer-
gency, and other specialist physicians. Multiple antibi-
otics were empirically prescribed for cellulitis, and these
differed significantly between the non-purulent and
purulent groups (Table 7). The rate of prescription of in-
appropriate antimicrobial agents was higher in the puru-
lent group than in the non-purulent group (46.2 % vs.
16.8 %, p < 0.001). Overuse of antibiotics is associated
with increased antibiotic resistance and cost of treat-
ment [30, 31]. However, inappropriately withholding
Table 7 Empirical prescription of antimicrobial agents. A. All cases of cellulitis B. Cases with pathogen isolated
A. Prescription of antimicrobial agents in all 465 cases of cellulitis
All (n = 465) Non-purulent group (n = 369) Purulent group (n = 96) P-value
Penicillin (%) 137 (29.5) 130 (35.2) 7 (7.3) <0.001
Oxacillin (%) 133 (28.6) 95 (25.7) 38 (39.6) 0.008
Cefazolin (%) 90 (19.4) 73 (19.8) 17 (17.7) 0.647
β-lactam/β-lactamase inhibitor (%) 17 (3.7) 9 (2.4) 8 (8.3) 0.012
Penicillin plus clindamycin (%) 16 (3.4) 16 (4.3) 0 (0.0) 0.052
Other (%) 72 (15.4) 46 (12.5) 26 (27.1) <0.001
B. Prevalence of appropriate antimicrobial agent in 211 cases with pathogen isolated
All (n = 211) Non-purulent group (n = 131) Purulent group (n = 80) P-value
Appropriate antimicrobial agent (%) 152 (72.0) 109 (83.2) 43 (53.8) <0.001
Data are number (%) of patients, unless otherwise indicated
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necessary antibiotics may have adverse effects on out-
comes. The impact of inappropriate antimicrobial agent
use on length of hospital stay, duration of antimicrobial
therapy and medical cost needs further analysis.
There has been much discussion as to whether cover-
age for CA-MRSA should be included in empirical regi-
mens for cellulitis. Published guidelines offer different
recommendations. The 2011 IDSA guidelines for MRSA
management recommend antimicrobial therapy target-
ing β-hemolytic streptococci for non-purulent cellulitis,
and specific CA-MRSA therapy for cases of purulent cel-
lulitis [15]. The 2014 IDSA guidelines for skin and soft
tissue infection management recommend antimicrobial
therapy effective against both MRSA and streptococci
for patients whose cellulitis is associated with penetrat-
ing trauma, evidence of MRSA infection elsewhere, nasal
colonization with MRSA, injection drug use, or systemic
inflammatory response syndrome [16]. However, there are
several issues that need to be addressed to provide an opti-
mal approach for the use of antibiotics in the management
of cellulitis. The diagnosis and management of cellulitis de-
pend largely on clinical features. Clinicians are often unwill-
ing to pursue microbiological diagnosis because of the
absence of culturable material in most cases of non-
purulent cellulitis, the relatively low recovery rate of patho-
gens [1], and favorable prognosis in most cases following
empirical therapy. Some primary physicians may use a
strategy known as double coverage, which refers to the use
of at least two antibiotics with Gram-positive coverage
(such as trimethoprim-sulfamethoxazole plus cephalexin)
to target MRSA, methicillin-sensitive S. aureus, and β-
hemolytic streptococci [32]. However, a recent randomized,
multicenter, double-blinded, placebo-controlled trial dem-
onstrated no improvement in outcomes among patients
with uncomplicated (non-purulent) cellulitis treated with
trimethoprim-sulfamethoxazole in addition to cephalexin
compared with those treated with cephalexin alone [33].
In the current study, MRSA was more frequently iso-
lated from the purulent group than the non-purulent
group (MRSA: 30.0 % vs. 6.1 %, p < 0.001). In multivari-
able analyses of factors that could be used for prediction
of MRSA infection, only purulence was a positive pre-
dictor of MRSA (OR, 5.188; 95 % CI, 1.995–13.493; p =
0.001). The lack of a significant difference in prevalence
of CA-MRSA between the two groups may be caused by
the small number of isolates (CA-MRSA: purulent vs.
non-purulent: 21.3 % vs. 3.8 %, p = 0.681). Initial empir-
ical antimicrobial therapy, when prescribed, must be
chosen based on local antimicrobial sensitivity data.
ST59-MRSA-VT/IV is the predominant CA-MRSA
clone in Taiwan [34, 35]. This clone is typically resistant
to erythromycin, clindamycin, and occasionally, gentami-
cin, but is susceptible to trimethoprim-sulfamethoxazole,
tetracyclines, and fluoroquinolones [34]. Because of the
retrospective nature of the present study, we were unable
to access the bacterial isolates for molecular epidemio-
logical studies. However, the antimicrobial sensitivity test-
ing of the 22 CA-MRSA isolates provided similar results.
The current study provides strong support for the
clinical approach recommended in the 2011 IDSA guide-
lines, dividing cellulitis into purulent and non-purulent
groups to help select the appropriate empirical anti-
microbial therapy to be applied in Taiwan. This consists
of β-lactam agents directed at streptococci for non-
purulent cellulitis, and antibiotics active against MRSA
for purulent cellulitis.
The major limitation of this study is information bias,
which is inherent in all retrospective studies. It also un-
avoidably contributes to selection bias because not all
patients received paired ASOT testing, and none of the
patients underwent a serological test for S. aureus. Both
of these factors may lead to an underestimate of the role
of β-hemolytic streptococci and S. aureus as etiological
agents of cellulitis. Additionally, our inability to differen-
tiate cutaneous abscess from purulent cellulitis may have
overestimated the number of cases in the purulent
group. The current study also only examined patients
from one hospital over a 1-year period. A multicenter-
study is needed to generalize our findings to all of
Taiwan. Prospective studies are needed to assess changes
that might occur regarding the predominant microor-
ganisms, and the emergence of antibiotic-resistant bac-
teria. Finally, the patients in this study were limited to
hospitalized cases, meaning that infections were more
severe. Therefore, the results of this study cannot be
generalized to all patients with cellulitis in Taiwan.
Conclusions
In conclusion, the epidemiology, clinical features, and
microbiology of purulent and non-purulent cellulitis
were significantly different in hospitalized Taiwanese
adults. Understanding the local epidemiology and etio-
logical agents is essential for the development of guide-
lines for empirical antimicrobial therapy of cellulitis in
Taiwan and other countries in South East Asia.
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